[Skin reactions to the Pfizer-BioNTech vaccine for COVID-19. An Ecuadorian experience].

Q3 Medicine

Revista alergia Mexico Pub Date : 2022-06-30 DOI:10.29262/ram.v69i1.973

Iván Chérrez-Ojeda, Karla Robles-Velasco, María F Osorio, Daniel Mejía-Leiva, Annia Chérrez, Sofía Chérrez, Jonathan A Bernstein, Zouina Sarfraz, Miguel Félix

{"title":"[Skin reactions to the Pfizer-BioNTech vaccine for COVID-19. An Ecuadorian experience].","authors":"Iván Chérrez-Ojeda, Karla Robles-Velasco, María F Osorio, Daniel Mejía-Leiva, Annia Chérrez, Sofía Chérrez, Jonathan A Bernstein, Zouina Sarfraz, Miguel Félix","doi":"10.29262/ram.v69i1.973","DOIUrl":null,"url":null,"abstract":"Objetive: To assess cutaneous reactions after Pfizer-BioNTech COVID-19 vaccine administration.Methods: A cross-sectional observational study was carried out in health workers belonging to the city of Guayaquil-Ecuador, from March to May 2021. The participants were contacted through a local registry established by the Universidad Espíritu Santo. Frequencies and percentages were used to represent the proportions of nominal variables, while the mean and standard deviation were used for continuous data, given a normal sample distribution.Results: Local skin reactions were the most frequent, and included redness, edema, and itching. On the other hand, delayed large local skin reactions (generalized rash and pruritus, angioedema, urticaria, eczema, petechiae) were rare and occurred in less than 1.4% of participants, (95% CI = 0.69-1.00). Finally, we did not find cases of anaphylaxis or other life-threatening reactions requiring urgent attention after vaccination.Conclusions: Our findings suggest that local skin reactions occur in a minority of recipients and are often mild and self-limited.","PeriodicalId":21175,"journal":{"name":"Revista alergia Mexico","volume":"69 1","pages":"61-64"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista alergia Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29262/ram.v69i1.973","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objetive: To assess cutaneous reactions after Pfizer-BioNTech COVID-19 vaccine administration.

Methods: A cross-sectional observational study was carried out in health workers belonging to the city of Guayaquil-Ecuador, from March to May 2021. The participants were contacted through a local registry established by the Universidad Espíritu Santo. Frequencies and percentages were used to represent the proportions of nominal variables, while the mean and standard deviation were used for continuous data, given a normal sample distribution.

Results: Local skin reactions were the most frequent, and included redness, edema, and itching. On the other hand, delayed large local skin reactions (generalized rash and pruritus, angioedema, urticaria, eczema, petechiae) were rare and occurred in less than 1.4% of participants, (95% CI = 0.69-1.00). Finally, we did not find cases of anaphylaxis or other life-threatening reactions requiring urgent attention after vaccination.

Conclusions: Our findings suggest that local skin reactions occur in a minority of recipients and are often mild and self-limited.

查看原文本刊更多论文

[对辉瑞- biontech COVID-19疫苗的皮肤反应。]厄瓜多尔人的经历]。

目的:评价辉瑞- biontech新冠肺炎疫苗接种后的皮肤反应。方法:于2021年3月至5月对厄瓜多尔瓜亚基尔市的卫生工作者进行了一项横断面观察研究。通过圣托大学(Espíritu Santo)设立的一个当地登记处与与会者取得联系。频率和百分比用于表示名义变量的比例，而平均值和标准差用于连续数据，给定正态样本分布。结果:局部皮肤反应最常见，包括红肿、瘙痒。另一方面，延迟的大面积局部皮肤反应(全身性皮疹和瘙痒、血管性水肿、荨麻疹、湿疹、瘀点)很少见，发生在不到1.4%的参与者中(95% CI = 0.69-1.00)。最后，我们没有发现接种疫苗后需要紧急关注的过敏反应或其他危及生命的反应。结论:我们的研究结果表明，局部皮肤反应发生在少数接受者中，通常是轻微的和自限性的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊